Octagon Capital Advisors »

Allogene Therapeutics shares owned by Octagon Capital Advisors

Quarter-by-quarter ownership of Allogene Therapeutics (ALLO) shares owned by Octagon Capital Advisors from 13F filings

Historical chart of Octagon Capital Advisors investment in Allogene Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Allogene Therapeutics held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Allogene Therapeutics by Octagon Capital Advisors

Quarter filed Position value Share count Share price at filing
2024-03-31 $3.2M 720k 4.47

More positions owned by Octagon Capital Advisors

Apellis Pharmaceuticals Call Option (APLS)
Alpine Immune Sciences (ALPN)
Dianthus Therapeutics (DNTH)
Verona Pharma Sponsored Ads (VRNA)
Dyne Therapeutics (DYN)
Arrivent Biopharma
Insmed Com Par $.01 (INSM)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Eyepoint Pharmaceuticals Com New (EYPT)
Ocular Therapeutix (OCUL)
Structure Therapeutics Sponsored Ads (GPCR)
Bridgebio Pharma (BBIO)
Mind Medicine Mindmed Com New (MNMD)
IsoRay (CATX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)

View all positions for Octagon Capital Advisors

Top funds holding Allogene Therapeutics

FMR
Tpg Gp A
BlackRock
Vanguard Group
PRIMECAP Management Company
Jpmorgan Chase & Co
T. Rowe Price Associates
Boxer Capital
Citadel Advisors
Frazier Life Sciences Management
Woodline Partners
Geode Capital Management
Morgan Stanley
Dimensional Fund Advisors
Two Sigma Investments

View all funds holding Allogene Therapeutics